Showing results (21-30 of 190) with videos related to
Sort By:
Pageof 19
Medical Oncology (Northwood, London, England)|January 13, 2004
Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosisKevin P O'Boyle, Ashwin Murigeppa, Dharamvir Jain, et al.Leukemia & Lymphoma|October 30, 2004
Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphomaDoru T Alexandrescu, Janice P Dutcher, Kevin O'Boyle, et al.American Journal of Hematology|December 21, 2004
Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three casesLydia Koulova, Doru Alexandrescu, Janice P Dutcher, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92)Peter H Wiernik, Janice P Dutcher, Xiapan Yao, et al.Oncology (Williston Park, N.Y.)|December 10, 2002
Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanomaJanice P DutcherCurrent Oncology Reports|January 31, 2004
Mammalian target of rapamycin (mTOR) InhibitorsJanice P DutcherLeukemia Research|March 22, 2003
The role of Epstein-Barr virus and elevated levels of tumor necrosis factor in determining prognosis in Asian peripheral T-cell lymphomasJanice P DutcherTherapeutic Advances in Urology|December 3, 2013
Recent developments in the treatment of renal cell carcinomaJanice P DutcherCancer Treatment and Research|December 4, 2003
Interleukin-2 based therapy for kidney cancerJanice P DutcherClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Mammalian target of rapamycin inhibitionJanice P DutcherPageof 19